JAB ‘EM YOUNG: FDA approves Pfizer’s booster vaccine for children aged 5 to 11 without consulting vaccine advisory panel

05/18/2022 / By Arsenio Toledo

The Food and Drug Administration (FDA) has just authorized booster doses of Pfizer’s Wuhan coronavirus (COVID-19) vaccine to be administered to children between the ages of five and 11 without convening its vaccine advisory panel.

The FDA made the announcement on Tuesday, May 17. Children in this age group can avail of a booster dose of Pfizer’s COVID-19 vaccine at least five months after the two-dose primary series.

Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said data shows that the so-called protection provided by two doses of Pfizer’s vaccine wanes over time. The solution, according to the FDA, is a booster dose that can supposedly offer more protection to children in this age group. (Related: Pfizer’s COVID-19 vaccine had a shocking DEATH rate of 3.7% during early trial – but the FDA approved it anyway.)

Marks added that the benefits of giving children aged five to 11 another dose of the experimental and deadly vaccine outweigh the risks.

The data the FDA is using is from an ongoing Pfizer trial in which a subset of 67 children aged five to 11 purportedly had higher antibody levels one month after receiving a booster Pfizer vaccine. The agency claims it did not notice any new safety concerns, but admitted that the children experienced similar side effects that other people feel after receiving a booster dose.

These side effects were noted as only being mild and they include swelling at the injection site, fatigue, headache, muscle or joint pain, chills and fever.

According to data from the Centers for Disease Control and Prevention (CDC), about 28 percent of American children aged five to 11 have received the primary series of two COVID-19 vaccine doses as of April. Both the FDA and the CDC are continuing to encourage parents to get their children vaccinated supposedly to protect them against the coronavirus.

FDA approved booster without consulting experts

The FDA made this announcement several days before it convened its vaccine advisory panel, composed of independent experts, to discuss Pfizer’s vaccine data on the age group.

Some members of this committee have informed CNBC that they have grown increasingly frustrated that the FDA has repeatedly moved ahead with its decisions regarding COVID-19 vaccines and boosters without consulting the advisory panel or holding open public discussions.

For its part, the CDC is set to convene its own committee of independent vaccine experts to discuss Pfizer vaccine boosters for children aged five to 11. These so-called vaccine experts are expected to issue a recommendation for or against the boosters.

But CDC Director Dr. Rochelle Walensky inevitably has the final say on whether healthcare providers can start administering the booster vaccines to the age group. Her decision usually supports the recommendations of the committee.

Once children aged five to 11 are given the final approval to receive booster vaccines, almost every age group in the U.S. will be eligible to receive three doses of the experimental and deadly vaccines with the exception of children under age five. Children in this age group are still not eligible for a primary vaccination series.

The FDA’s advisory committee is scheduled to meet next month to review Pfizer’s and Moderna’s requests to authorize their COVID-19 vaccines for children under the age of five.

Learn more about Pfizer’s COVID-19 vaccine at Vaccines.news.

Watch this episode of “The Highwire” as host Del Bigtree and co-host Jefferey Jaxen talk about how the FDA is still pushing the ineffective vaccines on children.

This video is from the High Hopes channel on Brighteon.com.